Ignite Creation Date:
2024-05-06 @ 6:57 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05846763
Status:
RECRUITING
Last Update Posted:
2023-05-23
First Post:
2023-04-27
Brief Title:
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
Sponsor:
Institute of Hematology Blood Diseases Hospital China
Organization:
Institute of Hematology Blood Diseases Hospital China
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-04-27
First Submit QC Date:
April 27 2023
Study First Post Date:
2023-05-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-21
Last Update Post Date:
2023-05-23
Last Update Post Date Type:
ACTUAL